Astrazeneca Surges 9.96% on $1.2 Billion Volume Spike, Ranks 101st in Market Activity

Astrazeneca (AZN) surged 9.96% on October 1, 2025, with a trading volume of $1.2 billion—a 105.28% increase from the previous day—ranking 101st in market activity. The move followed a strategic shift in its oncology pipeline, including accelerated regulatory submissions for two mid-stage cancer therapies. Analysts noted the development could enhance long-term revenue visibility, particularly in high-growth therapeutic areas.

The stock’s performance was further supported by renewed investor confidence in its R&D efficiency metrics, with third-quarter data showing a 20% reduction in clinical trial timelines compared to industry benchmarks. Institutional buying pressure intensified following a positive FDA advisory panel vote on a companion diagnostic tool linked to its flagship immuno-oncology candidate. Market participants interpreted the regulatory progress as a catalyst for near-term commercialization.

To run this study robustly, I need to pin down a couple of practical details: 1. Universe – Which market should we scan each day to find the “top-500-by-volume” names? 2. Weighting & execution price – Equal-weight each of the 500 names? 3. Cash management – Invest 100% of available cash every day (no leverage)? Once those points are confirmed, I can generate the daily trade lists, build the consolidated P&L series, and present a full back-test report (equity curve, drawdowns, stats).